A 24-year-old woman with CML underwent allogeneic BMT in August 1995 from a one-antigen HLA mismatched brother. Conditioning included BuCy2 and CsA and MTX were used to prevent GVHD. In July 1997 she developed right leg pain, lytic bone lesions of distal femur and a solid mass of soft tissue. Histological diagnosis of malignant fibrous histiocytoma was made. Despite treatment with surgery and chemotherapy (doxorubicin and ifosfamide), the patient died 1 year later with local recurrence of the tumor and liver, lung and brain metastases. The CML was in CR.
/day subcutaneously for an 18 month period and achieved hematologic response with no cytogenetic remission. In August 1995 an allogeneic BMT was performed from a one-antigen HLA mismatched brother. Conditioning included Bu 16 mg/kg and Cy 120 mg/kg. CsA and MTX were used to prevent GVHD. The post-transplant course was unremarkable apart from grade I acute skin GVHD. CsA was slowly tapered and then discontinued at +180 days. In July 1996, CMV viremia was diagnosed (positive shell vial culture and pp65 antigen) and treated with gancyclovir 5 mg/kg every 12 h for 14 days and then twice a week for 2 months. No chronic GVHD was observed. In July 1997, right leg pain developed. X-rays showed lytic bone lesions of the distal Correspondence: Dr J Vela-Ojeda, Hospital de Especialidades, Centro Médico Nacional La Raza, IMSS, Apartado postal 14-878, código postal 07001 Mexico DF, Mexico Received 13 July 1998; accepted 22 March 1999 femur (Figure 1) , and CT scan demonstrated a solid mass (3.8 × 4.6 cm) of the surrounding soft tissue (Figures 2 and  3 ). The mass was surgically excised and a histological diagnosis of malignant fibrous histiocytoma (MFH) of soft tissue with right femur involvement ( Figure 4 ) was made. Metastatic workup was negative. Salvage limb surgery (resection of femur with myectomy and prosthesis application) was performed; the surgical margins were negative. BM, cytogenetic and molecular analysis (PCR for bcr/abl) were negative for CML relapse. Adjuvant chemotherapy consisted of doxorubicin 50 mg/m 2 and ifosfamide 5 g/m 2 every month for a total of five courses with complete response achieved in December 1997. In February 1998 examination detected a tender unmovable mass on the right leg. In March 1998 lung and liver metastases were discovered. The patient died in July 1998 with local recurrence and lung, liver and brain metastases. She was in complete hematologic, cytogenetic (46 XY with no Ph chromosome) and molecular remission of CML.
Discussion
BMT is a widely accepted therapeutic modality for hematologic malignancies, solid tumors and certain nonmalignant disorders. With the improvement in survival, second neoplasms are a serious complication in this group of patients. 1 The etiology of second malignancy is multifactorial and may include immune deficiency resulting in EBV associated B cell lymphoproliferative disease (BLPD), irradiation and possibly chemotherapy resulting in leukemias and solid nonhematopoietic tumors and finally an interaction of any of these factors with genetic predisposition resulting in a variety of malignancies. 2 The risk of second solid cancers in recipients of BMT is higher than the general population and 8.3 times as high as expected among those who have survived 10 or more years after BMT. 3 The most frequent secondary solid cancers are malignant melanoma, cancers of the buccal cavity, liver, brain, thyroid, bone and connective tissue.
MFH is the commonest soft tissue sarcoma (50-60%) 4 and the most common post-radiation soft tissue sarcoma accounting for 40% of cases; 5 however, it is a rare secondary malignancy after BMT. To our knowledge there are five other cases reported. Bhatia et al 2 in a series of 51 patients with secondary malignant neoplasms, studied one patient with MFH, and Curtis et al 3 in the largest group of patients with solid cancers after BMT, reported two of three liver cancers as MFH. Iori et al 6 reported an 11-year-old patient with AML and secondary MFH of the pectoral muscle 18 months after BMT, and Pesce et al 7 studied the case of a 30-year-old man with AML who developed MFH of the right femur 8 years after BMT. All patients had received TBI as conditioning prior to BMT. In our patient the only risk factor for secondary cancer was the use of a one-antigen mismatched donor.
Alkylating agents such as Bu and Cy can produce mutagenic effects by chromosome loss, alteration of repair of O 6 -guanine adducts or DNA base mispairing, 8 although the projected probability of developing a secondary malignancy at 15 years is 6% for patients prepared with chemotherapy before BMT and 20% for those conditioned with TBI. 9 In the study of 700 patients with severe aplastic anemia transplanted in Seattle and Paris, 10 eight solid tumors developed in 445 patients who had not received irradiation and 10 solid tumors occurred in 225 patients who had received irradiation. In children, treatment with alkylating agents is linked to the development of secondary bone sarcomas with a relative risk of 4.7, risk increasing as the cumulative drug exposure rose. We conclude that rare secondary cancers can be diagnosed even early after BMT. Genetic predisposition and the use of alkylating agents are possible explanations.
